Objectives ATHENA evaluated the cobas HPV Test as the primary screen for cervical cancer
in women≥ 25 years. This reports the 3-year end-of-study results comparing the …

Background Screening for cervical cancer based on testing for human papillomavirus (HPV)
increases the sensitivity of detection of high-grade (grade 2 or 3) cervical intraepithelial …

Background In the first recruitment phase of a randomized trial of cervical cancer screening
methods (New Technologies for Cervical Cancer Screening [NTCC] study), we compared …

Despite its history of success in cancer screening, Pap cytology has important limitations,
particularly its high false-negative rate, which carries important public health implications …

OBJECTIVE: This is a meta-analysis of studies comparing HPV testing to cytology with
regard to their accuracy in the detection of underlying high grade cervical intraepithelial …

The Canadian Cervical Cancer Screening Trial was a randomized controlled trial comparing
the performance of human papillomavirus (HPV) testing and Papanicolaou cytology to …

Several studies suggest that HPV testing is more sensitive than cytology in primary cervical
screening. These studies had different designs and were reported in different ways …

Cytology-based cervical screening had unequivocal success in reducing the incidence and
mortality of cervical cancer in the last century. The recognition of the role of human …

BACKGROUND In the United States, human papillomavirus (HPV) and Papanicolaou (Pap)
testing (cotesting) for cervical screening in women ages 30 to 65 years is the preferred …

Complete Round 1 data (baseline and 12‐month follow‐up) for HPV FOCAL, a randomized
trial establishing the efficacy of HPV DNA testing with cytology triage as a primary screen for …